繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

OS Therapies Announced That The Last Patient Enrolled In AOST-2121 Clinical Trial Of OST-HER2 In Recurred, Resected Osteosarcoma Has Received Its Last Treatment Dose, Primary Endpoint Analysis Is Expected By Early In The Fourth Quarter Of 2024

2024-08-29 19:58

This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Event Free Survival primary endpoint analysis by early in the fourth quarter of 2024. Concurrently, the Company will close all clinical trial sites and lock the database in preparation for data analysis and topline data readout that is expected to be announced in the fourth quarter of 2024. 

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。